CARTESIAN THERAPEUTICS INC (RNAC) — insider trading
Health Care · NASDAQ
CARTESIAN THERAPEUTICS INC (RNAC) has 20 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 20 (latest 2026-04-02).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-04-02 | Kalayoglu Murat | 10% owner | Option exercise / conversion (derivative) | 22,740 | — | — | Form 4 |
| 2026-04-02 | Kalayoglu Murat | 10% owner | Option exercise / conversion | 758,001 | — | — | Form 4 |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust | 10% owner | Option exercise / conversion (derivative) | 22,740 | — | — | Form 4 |
| 2026-04-02 | Hoge Elizabeth; Seven One Eight Three Four Irrevocable Trust | 10% owner | Option exercise / conversion | 758,001 | — | — | Form 4 |
| 2026-03-13 | Singer Michael | Director | Bona fide gift | 6,555 | — | $0 | Form 4 |
| 2026-01-06 | Davis Blaine | Officer (Chief Financial Officer) | Open-market sale | 10,591 | $6.82 | $72.2K | Form 4 |
| 2026-01-06 | Miljkovic Milos | Officer (Chief Medical Officer) | Open-market sale | 3,573 | $6.82 | $24.4K | Form 4 |
| 2026-01-06 | Brunn Carsten | Director, Officer (President and CEO) | Open-market sale | 23,766 | $6.82 | $162.1K | Form 4 |
| 2026-01-02 | Seymour June Ann | Officer (Chief Accounting Officer) | Grant / award / vesting (derivative) | 19,000 | — | $0 | Form 4 |
| 2026-01-02 | Seymour June Ann | Officer (Chief Accounting Officer) | Grant / award / vesting | 6,500 | — | $0 | Form 4 |
| 2026-01-02 | ZENNER PATRICK J | Director | Grant / award / vesting (derivative) | 7,800 | — | $0 | Form 4 |
| 2026-01-02 | ZENNER PATRICK J | Director | Grant / award / vesting | 2,600 | — | $0 | Form 4 |
| 2026-01-02 | Miljkovic Milos | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 77,000 | — | $0 | Form 4 |
| 2026-01-02 | Miljkovic Milos | Officer (Chief Medical Officer) | Grant / award / vesting | 27,000 | — | $0 | Form 4 |
| 2026-01-02 | Malik Kemal | Director | Grant / award / vesting (derivative) | 7,800 | — | $0 | Form 4 |
| 2026-01-02 | Malik Kemal | Director | Grant / award / vesting | 2,600 | — | $0 | Form 4 |
| 2026-01-02 | Brunn Carsten | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 415,700 | — | $0 | Form 4 |
| 2026-01-02 | Brunn Carsten | Director, Officer (President and CEO) | Grant / award / vesting | 143,200 | — | $0 | Form 4 |
| 2026-01-02 | DeSilva Nishan M | Director | Grant / award / vesting (derivative) | 7,800 | — | $0 | Form 4 |
| 2026-01-02 | DeSilva Nishan M | Director | Grant / award / vesting | 2,600 | — | $0 | Form 4 |
Ask the chat about RNAC's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: CARTESIAN THERAPEUTICS INC (RNAC).
Last updated 2026-04-02 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.